Global Investor
Book store My basket Sign in Join Now - It's FREE!
Home Financial Directory Funds Research Events Glossary Store FAQs News Jobs / HR
 On The Take: How Medicine's Complicity with Big Business Can Endanger Your Health
Financial Shop
DVDs
Videos
Magazines
Search Books:
Type any part of a name:

On The Take: How Medicine's Complicity with Big Business Can Endanger Your Health

On The Take: How Medicine's Complicity with Big Business Can Endanger Your Health
Publisher
 Oxford University Press
Published
 September 2004
ISBN
 0195176847
$28.00 List Price
$18.48 OUR PRICE
Sales Rank: 11,180
AVAILABILITY:
Usually ships in 24 hours

We all know that doctors accept gifts from drug companies, ranging from pens and coffee mugs to free vacations at luxurious resorts. But as the former Editor-in-Chief of The New England Journal of Medicine reveals in this shocking expose, these innocuous-seeming gifts are just the tip of an iceberg that is distorting the practice of medicine and jeopardizing the health of millions of Americans today. In On the Take, Dr. Jerome Kassirer offers an unsettling look at the pervasive payoffs that physicians take from big drug companies and other medical suppliers, arguing that the billion-dollar onslaught of industry money has deflected many physicians' moral compasses and directly impacted the everyday care we receive from the doctors and institutions we trust most. Underscored by countless chilling untold stories, the book illuminates the financial connections between the wealthy companies that make drugs and the doctors who prescribe them. Kassirer details the shocking extent of these financial enticements and explains how they encourage bias, promote dangerously misleading medical information, raise the cost of medical care, and breed distrust. Among the questionable practices he describes are: the disturbing number of senior academic physicians who have financial arrangements with drug companies; the unregulated "front" organizations that advocate certain drugs; the creation of biased medical education materials by the drug companies themselves; and the use of financially conflicted physicians to write clinical practice guidelines or to testify before the FDA in support of a particular drug. A brilliant diagnosis of an epidemic of greed, On the Take offers insight into how we can cure the medical profession and restore our trust in doctors and hospitals.

Product Reviews

Review this item. Coming soon!
Average rating: 5.0
essential reading Rating
January 26, 2005 Rating: 5.0 stars

I rarely write reviews, but in this case feel obligated to point out what a tremendous service Dr. Kassirer has provided. As a physician, I have always been concerned about the influence of gifts and outright payments to doctors and researchers in promoting pharmaceuticals and other healthcare. However, I had no idea how extensive and pervasive it is. Dr. Kassirer has done an outstanding job in giving us a picture of the truth. This is a very well written book. I strongly recommend that all medical students and physicians read it, and suggest that everyone interested in healthcare do so.

As a minor point: Dr. Kassirer does not address the same influence which is present in alternative and complementary medicine--whose practitioners often benefit from the negative press of scientific (allopathic) medicine. In fact, it is just as bad or even worse in those types of care.

Finally, I must point out that I have never met Dr. Kassirer and have no financial inducement to write this :-)

Paul Gahlinger, MD, PhD

The Corrupting Influence of Big Money on Physicians Rating
January 26, 2005 Rating: 5.0 stars

Dr. Jerome Kassirer is the former editor of the New England Journal of Medicine and a physician-educator with impeccable credentials. He has written an insightful and illuminating analysis of how big business money has harmed physicians and the patients they serve. This volume is a must read for physicians who have experienced some of the events described in the book and for patients whose interactions with their physicians may have been influenced in ways that they couldn't have appreciated.

Much of the book focuses on the activities of pharmaceutical
companies that spend more than $30,000 per year on each U.S. physician to promote and market products. Physicians have been exposed to a variety of marketing tactics over a period of years. The resulting changes in physician behavior, e.g. conflicts of interest, erode the core of trust that binds physicians and their patients together. These conflicts of interest also taint the information physicians rely on to treat their patients. Dr Kassirer also focuses on medical journals, professional organizations, research organizations and prestigious federal agencies that have been coopted by the insidious influence of big business money.

The book provides an analysis of how this problem has developed and makes specific suggestions on treatment. Although the writing is hard-hitting, it is balanced and fair. The problem is huge. This book may do just what Dr. Kassirer requests: initiate a sustained public outcry against inappropriate practices.

essential reading Rating
January 26, 2005 Rating: 5.0 stars

I rarely write reviews, but in this case feel obligated to point out what a tremendous service Dr. Kassirer has provided. As a physician, I have always been concerned about the influence of gifts and outright payments to doctors and researchers in promoting pharmaceuticals and other healthcare. However, I had no idea how extensive and pervasive it is. Dr. Kassirer has done an outstanding job in giving us a picture of the truth. This is a very well written book. I strongly recommend that all medical students and physicians read it, and suggest that everyone interested in healthcare do so.

As a minor point: Dr. Kassirer does not address the same influence which is present in alternative and complementary medicine--whose practitioners often benefit from the negative press of scientific (allopathic) medicine. In fact, it is just as bad or even worse in those types of care.

Finally, I must point out that I have never met Dr. Kassirer and have no financial inducement to write this :-)

Paul Gahlinger, MD, PhD

The Corrupting Influence of Big Money on Physicians Rating
January 26, 2005 Rating: 5.0 stars

Dr. Jerome Kassirer is the former editor of the New England Journal of Medicine and a physician-educator with impeccable credentials. He has written an insightful and illuminating analysis of how big business money has harmed physicians and the patients they serve. This volume is a must read for physicians who have experienced some of the events described in the book and for patients whose interactions with their physicians may have been influenced in ways that they couldn't have appreciated.

Much of the book focuses on the activities of pharmaceutical
companies that spend more than $30,000 per year on each U.S. physician to promote and market products. Physicians have been exposed to a variety of marketing tactics over a period of years. The resulting changes in physician behavior, e.g. conflicts of interest, erode the core of trust that binds physicians and their patients together. These conflicts of interest also taint the information physicians rely on to treat their patients. Dr Kassirer also focuses on medical journals, professional organizations, research organizations and prestigious federal agencies that have been coopted by the insidious influence of big business money.

The book provides an analysis of how this problem has developed and makes specific suggestions on treatment. Although the writing is hard-hitting, it is balanced and fair. The problem is huge. This book may do just what Dr. Kassirer requests: initiate a sustained public outcry against inappropriate practices.

essential reading Rating
January 26, 2005 Rating: 5.0 stars

I rarely write reviews, but in this case feel obligated to point out what a tremendous service Dr. Kassirer has provided. As a physician, I have always been concerned about the influence of gifts and outright payments to doctors and researchers in promoting pharmaceuticals and other healthcare. However, I had no idea how extensive and pervasive it is. Dr. Kassirer has done an outstanding job in giving us a picture of the truth. This is a very well written book. I strongly recommend that all medical students and physicians read it, and suggest that everyone interested in healthcare do so.

As a minor point: Dr. Kassirer does not address the same influence which is present in alternative and complementary medicine--whose practitioners often benefit from the negative press of scientific (allopathic) medicine. In fact, it is just as bad or even worse in those types of care.

Finally, I must point out that I have never met Dr. Kassirer and have no financial inducement to write this :-)

Paul Gahlinger, MD, PhD

The Corrupting Influence of Big Money on Physicians Rating
January 26, 2005 Rating: 5.0 stars

Dr. Jerome Kassirer is the former editor of the New England Journal of Medicine and a physician-educator with impeccable credentials. He has written an insightful and illuminating analysis of how big business money has harmed physicians and the patients they serve. This volume is a must read for physicians who have experienced some of the events described in the book and for patients whose interactions with their physicians may have been influenced in ways that they couldn't have appreciated.

Much of the book focuses on the activities of pharmaceutical
companies that spend more than $30,000 per year on each U.S. physician to promote and market products. Physicians have been exposed to a variety of marketing tactics over a period of years. The resulting changes in physician behavior, e.g. conflicts of interest, erode the core of trust that binds physicians and their patients together. These conflicts of interest also taint the information physicians rely on to treat their patients. Dr Kassirer also focuses on medical journals, professional organizations, research organizations and prestigious federal agencies that have been coopted by the insidious influence of big business money.

The book provides an analysis of how this problem has developed and makes specific suggestions on treatment. Although the writing is hard-hitting, it is balanced and fair. The problem is huge. This book may do just what Dr. Kassirer requests: initiate a sustained public outcry against inappropriate practices.

Big Pharma Out of Control Rating
January 19, 2005 Rating: 5.0 stars

Fact-dense, well referenced, yet balanced in tone and easy to read, this book is the best exposé I have ever read on the financial conflicts of the medical profession caused by the efforts of Big Pharma, which for this review will include device and test manufacturers as well as drug makers. From pens and pads to cruises and fake consulting arrangements, Big Pharma has caused financial conflicts in many physicians and others "on the take". Many of the consulting deals are to give talks, ostensibly based on good medical science, that promote a product. Much of this is shown to occur at Continuing Medical Education courses sponsored by Big Pharma in which gifts are freely dispensed, reprints of journal articles favorable to products are handed out, and financial ties of the "consultants" giving talks are minimized or concealed.

Academic researchers are tainted as well. By being encouraged by their universities to obtain grants with overhead from Big Pharma, they must do research that helps in product development. Agreements may delay, prevent or pollute the publication of results. When a product possibility from a government (usually NIH) grant is seen, federal legislation passed 20 years ago allows the researcher to patent discoveries, form a company, and do clinical trials on his own potential product. While this may have led to valuable results, the potential for bias at every step due to financial conflict is clearly laid out.

Journals fare little better, even the prominent JAMA, NEJM and Annals of Internal Medicine. Papers that may have been ghost-written by Big Pharma on clinical trials with selectively favorable results are published [see Joel M. Kauffman, Bias in Recent Papers on Diets and Drugs in Peer-Reviewed Medical Journals, J. Am. Physicians & Surgeons, 9(1), 11-14 (2004)]. Editors and peer-reviewers may have ties to Big Pharma. Editorials and comments in medical journals may be written by authors with financial conflicts of interest. Revealing such conflicts is mostly on the honor system at present.

Clinical guidelines for physicians are promulgated by committees whose members often have close ties to Big Pharma. The products included in formularies of HMOs, Medicare and other insurers, the only products that will be paid for, are influenced by Big Pharma, whose general lobbying efforts are already legendary.

Dr. Kassirer gives many specific examples of financial conflicts. Far from quitting with the devastating description of how bad things are, he goes on to make specific suggestions for reform, while being very realistic about their success without federal action for certain conflicts. He lists many desirable changes, such as no gifts from Big Pharma at all, boycotting meetings sponsored by Big Pharma, disclosure mandated for all financial ties, and selection of journal editors, officers of medical societies and leaders of medical schools who have no financial conflicts. He did not seem to indicate the degree of influence of Big Pharma on the FDA.

Trying not to alienate most of the medical profession, Dr. Kassirer wrote that most MDs are basically ethical and went into the profession for non-financial as well as financial reasons. Reductions in income with increased work loads due to inadequate compensation from HMOs and Medicare is one of the reasons so many MDs have looked outside normal practice for income.
******
He dropped a few hints that most major classes of drugs are more beneficial than they actually are [see Joel M. Kauffman, "Drugging Cardiovascular Disease", J. Am. Physicians & Surgeons, 9(4), 98-99 (2004)], and that alternative practices are not worth much [see Joel M. Kauffman, "Alternative Medicine: Watching the Watchdogs at Quackwatch", Website Review, J. Scientific Exploration 16(2), 312-337 (2002)].
This is a very minor blemish on one of the great exposés of all time, the "Unsafe at Any Speed" of the medical madness in the USA today.
******
Daniel Haley's "Politics in Healing" describes the squashing of alternatives.
Charles T. McGee's "Heart Frauds" exposes the mythology behind so much medical advice.
H. Gilbert Welch's "Should I Be Tested for Cancer?" gives the evidence for the harm in excessive testing.
John Anderson's "Overdosed America" reveals the extent of perverted clinical drug trials.
Merrill Goozner's "The $800 Million Pill" give the lie to Big Pharma's claim that high prices are needed for the discovery of breakthrough drugs, as does...
Marcia Angell's "The Truth About the Drug Companies", which also suggests how the perversion of drug trials can be halted.

Big Pharma Out of Control Rating
January 19, 2005 Rating: 5.0 stars

Fact-dense, well referenced, yet balanced in tone and easy to read, this book is the best exposé I have ever read on the financial conflicts of the medical profession caused by the efforts of Big Pharma, which for this review will include device and test manufacturers as well as drug makers. From pens and pads to cruises and fake consulting arrangements, Big Pharma has caused financial conflicts in many physicians and others "on the take". Many of the consulting deals are to give talks, ostensibly based on good medical science, that promote a product. Much of this is shown to occur at Continuing Medical Education courses sponsored by Big Pharma in which gifts are freely dispensed, reprints of journal articles favorable to products are handed out, and financial ties of the "consultants" giving talks are minimized or concealed.

Academic researchers are tainted as well. By being encouraged by their universities to obtain grants with overhead from Big Pharma, they must do research that helps in product development. Agreements may delay, prevent or pollute the publication of results. When a product possibility from a government (usually NIH) grant is seen, federal legislation passed 20 years ago allows the researcher to patent discoveries, form a company, and do clinical trials on his own potential product. While this may have led to valuable results, the potential for bias at every step due to financial conflict is clearly laid out.

Journals fare little better, even the prominent JAMA, NEJM and Annals of Internal Medicine. Papers that may have been ghost-written by Big Pharma on clinical trials with selectively favorable results are published [see Joel M. Kauffman, Bias in Recent Papers on Diets and Drugs in Peer-Reviewed Medical Journals, J. Am. Physicians & Surgeons, 9(1), 11-14 (2004)]. Editors and peer-reviewers may have ties to Big Pharma. Editorials and comments in medical journals may be written by authors with financial conflicts of interest. Revealing such conflicts is mostly on the honor system at present.

Clinical guidelines for physicians are promulgated by committees whose members often have close ties to Big Pharma. The products included in formularies of HMOs, Medicare and other insurers, the only products that will be paid for, are influenced by Big Pharma, whose general lobbying efforts are already legendary.

Dr. Kassirer gives many specific examples of financial conflicts. Far from quitting with the devastating description of how bad things are, he goes on to make specific suggestions for reform, while being very realistic about their success without federal action for certain conflicts. He lists many desirable changes, such as no gifts from Big Pharma at all, boycotting meetings sponsored by Big Pharma, disclosure mandated for all financial ties, and selection of journal editors, officers of medical societies and leaders of medical schools who have no financial conflicts. He did not seem to indicate the degree of influence of Big Pharma on the FDA.

Trying not to alienate most of the medical profession, Dr. Kassirer wrote that most MDs are basically ethical and went into the profession for non-financial as well as financial reasons. Reductions in income with increased work loads due to inadequate compensation from HMOs and Medicare is one of the reasons so many MDs have looked outside normal practice for income.
******
He dropped a few hints that most major classes of drugs are more beneficial than they actually are [see Joel M. Kauffman, "Drugging Cardiovascular Disease", J. Am. Physicians & Surgeons, 9(4), 98-99 (2004)], and that alternative practices are not worth much [see Joel M. Kauffman, "Alternative Medicine: Watching the Watchdogs at Quackwatch", Website Review, J. Scientific Exploration 16(2), 312-337 (2002)].
This is a very minor blemish on one of the great exposés of all time, the "Unsafe at Any Speed" of the medical madness in the USA today.
******
Daniel Haley's "Politics in Healing" describes the squashing of alternatives.
Charles T. McGee's "Heart Frauds" exposes the mythology behind so much medical advice.
H. Gilbert Welch's "Should I Be Tested for Cancer?" gives the evidence for the harm in excessive testing.
John Anderson's "Overdosed America" reveals the extent of perverted clinical drug trials.
Merrill Goozner's "The $800 Million Pill" give the lie to Big Pharma's claim that high prices are needed for the discovery of breakthrough drugs, as does...
Marcia Angell's "The Truth About the Drug Companies", which also suggests how the perversion of drug trials can be halted.

Big Pharma Out of Control Rating
January 19, 2005 Rating: 5.0 stars

Fact-dense, well referenced, yet balanced in tone and easy to read, this book is the best exposé I have ever read on the financial conflicts of the medical profession caused by the efforts of Big Pharma, which for this review will include device and test manufacturers as well as drug makers. From pens and pads to cruises and fake consulting arrangements, Big Pharma has caused financial conflicts in many physicians and others "on the take". Many of the consulting deals are to give talks, ostensibly based on good medical science, that promote a product. Much of this is shown to occur at Continuing Medical Education courses sponsored by Big Pharma in which gifts are freely dispensed, reprints of journal articles favorable to products are handed out, and financial ties of the "consultants" giving talks are minimized or concealed.

Academic researchers are tainted as well. By being encouraged by their universities to obtain grants with overhead from Big Pharma, they must do research that helps in product development. Agreements may delay, prevent or pollute the publication of results. When a product possibility from a government (usually NIH) grant is seen, federal legislation passed 20 years ago allows the researcher to patent discoveries, form a company, and do clinical trials on his own potential product. While this may have led to valuable results, the potential for bias at every step due to financial conflict is clearly laid out.

Journals fare little better, even the prominent JAMA, NEJM and Annals of Internal Medicine. Papers that may have been ghost-written by Big Pharma on clinical trials with selectively favorable results are published [see Joel M. Kauffman, Bias in Recent Papers on Diets and Drugs in Peer-Reviewed Medical Journals, J. Am. Physicians & Surgeons, 9(1), 11-14 (2004)]. Editors and peer-reviewers may have ties to Big Pharma. Editorials and comments in medical journals may be written by authors with financial conflicts of interest. Revealing such conflicts is mostly on the honor system at present.

Clinical guidelines for physicians are promulgated by committees whose members often have close ties to Big Pharma. The products included in formularies of HMOs, Medicare and other insurers, the only products that will be paid for, are influenced by Big Pharma, whose general lobbying efforts are already legendary.

Dr. Kassirer gives many specific examples of financial conflicts. Far from quitting with the devastating description of how bad things are, he goes on to make specific suggestions for reform, while being very realistic about their success without federal action for certain conflicts. He lists many desirable changes, such as no gifts from Big Pharma at all, boycotting meetings sponsored by Big Pharma, disclosure mandated for all financial ties, and selection of journal editors, officers of medical societies and leaders of medical schools who have no financial conflicts. He did not seem to indicate the degree of influence of Big Pharma on the FDA.

Trying not to alienate most of the medical profession, Dr. Kassirer wrote that most MDs are basically ethical and went into the profession for non-financial as well as financial reasons. Reductions in income with increased work loads due to inadequate compensation from HMOs and Medicare is one of the reasons so many MDs have looked outside normal practice for income.
******
He dropped a few hints that most major classes of drugs are more beneficial than they actually are [see Joel M. Kauffman, "Drugging Cardiovascular Disease", J. Am. Physicians & Surgeons, 9(4), 98-99 (2004)], and that alternative practices are not worth much [see Joel M. Kauffman, "Alternative Medicine: Watching the Watchdogs at Quackwatch", Website Review, J. Scientific Exploration 16(2), 312-337 (2002)].
This is a very minor blemish on one of the great exposés of all time, the "Unsafe at Any Speed" of the medical madness in the USA today.
******
Daniel Haley's "Politics in Healing" describes the squashing of alternatives.
Charles T. McGee's "Heart Frauds" exposes the mythology behind so much medical advice.
H. Gilbert Welch's "Should I Be Tested for Cancer?" gives the evidence for the harm in excessive testing.
John Anderson's "Overdosed America" reveals the extent of perverted clinical drug trials.
Merrill Goozner's "The $800 Million Pill" give the lie to Big Pharma's claim that high prices are needed for the discovery of breakthrough drugs, as does...
Marcia Angell's "The Truth About the Drug Companies", which also suggests how the perversion of drug trials can be halted.

A call to medicine's conscience and warning to consumers Rating
November 5, 2004 Rating: 5.0 stars

Dr. Kassirer, Distinguished Professor in Tufts University School of Medicine and former Editor-in-Chief of the prestigious New England Journal of Medicine, is a representative of the medical profession of another era which earned and retained our confidence and respect. His book is a call to the physicians today to resist the insidious effects of subtle and not-so-subtle conflicts of interest in accepting funding from the pharmaceutical industry. Scores of examples are documented of greed, venality, laziness and ignorance which have led physicians and professional organizations to compromise their integrity in the quest for financial support. As Executive Vice-President of the American Heart Association's New York City Affiliate for thirty years I personally watched this corrosive influence tempt and occasionally even subvert this once-proud organization into compromising its intellectual standards. Dr. Kassirer indicates that in the ten years since I retired, their resistance has weakened. The book is a must-read for physicians of conscience and a warning to consumers to be careful where they place their trust.

A call to medicine's conscience and warning to consumers Rating
November 5, 2004 Rating: 5.0 stars

Dr. Kassirer, Distinguished Professor in Tufts University School of Medicine and former Editor-in-Chief of the prestigious New England Journal of Medicine, is a representative of the medical profession of another era which earned and retained our confidence and respect. His book is a call to the physicians today to resist the insidious effects of subtle and not-so-subtle conflicts of interest in accepting funding from the pharmaceutical industry. Scores of examples are documented of greed, venality, laziness and ignorance which have led physicians and professional organizations to compromise their integrity in the quest for financial support. As Executive Vice-President of the American Heart Association's New York City Affiliate for thirty years I personally watched this corrosive influence tempt and occasionally even subvert this once-proud organization into compromising its intellectual standards. Dr. Kassirer indicates that in the ten years since I retired, their resistance has weakened. The book is a must-read for physicians of conscience and a warning to consumers to be careful where they place their trust.

A call to medicine's conscience and warning to consumers Rating
November 5, 2004 Rating: 5.0 stars

Dr. Kassirer, Distinguished Professor in Tufts University School of Medicine and former Editor-in-Chief of the prestigious New England Journal of Medicine, is a representative of the medical profession of another era which earned and retained our confidence and respect. His book is a call to the physicians today to resist the insidious effects of subtle and not-so-subtle conflicts of interest in accepting funding from the pharmaceutical industry. Scores of examples are documented of greed, venality, laziness and ignorance which have led physicians and professional organizations to compromise their integrity in the quest for financial support. As Executive Vice-President of the American Heart Association's New York City Affiliate for thirty years I personally watched this corrosive influence tempt and occasionally even subvert this once-proud organization into compromising its intellectual standards. Dr. Kassirer indicates that in the ten years since I retired, their resistance has weakened. The book is a must-read for physicians of conscience and a warning to consumers to be careful where they place their trust.

Privacy Sitemap About us

Disclaimer:

The information on this site is for informational purposes only.   globalinvestor.com its affiliates and content licensors assume no liability for any inaccurate, delayed or incomplete information, nor for any actions taken in reliance thereon. The information contained about each individual and firm has been supplied by such individual or firm without verification by us. Past performance is not necessarily indicative of future performance. Prior to making any investment decision, it is recommended that you consult directly with the individual or firm and seek advice from a qualified investment advisor.

-
-